The Immune Tolerance Network at 10 years: Tolerance research at the bedside

Nature Reviews Immunology

Volumn 10, Issue 11, 2010, Pages 797-803

  Bluestone, Jeffrey A ^a   Auchincloss, Hugh ^b   Nepom, Gerald T ^c   Rotrosen, Daniel ^b   St Clair, E William ^d   Turka, Laurence A ^e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c BENAROYA RESEARCH INSTITUTE   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGY; ANTIGEN SPECIFICITY; AUTOIMMUNE DISEASE; CLINICAL RESEARCH; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOLOGICAL TOLERANCE; NONHUMAN; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; REVIEW;

ANIMALS; CLINICAL TRIALS AS TOPIC; GOVERNMENT PROGRAMS; HUMANS; IMMUNE SYSTEM DISEASES; IMMUNE TOLERANCE; NATIONAL INSTITUTES OF HEALTH (U.S.); UNITED STATES;

EID: 77958604019     PISSN: 14741733     EISSN: None     Source Type: Journal    
DOI: 10.1038/nri2869     Document Type: Review

References (45)

1. Girlanda, R. & Kirk, A. D. Frontiers in nephrology: immune tolerance to allografts in humans. J. Am. Soc. Nephrol. 18, 2242-2251 (2007).
2. Lenschow, D. J. & Bluestone, J. A. T cell co-stimulation and in vivo tolerance. Curr. Opin. Immunol. 5, 747-752 (1993).
3. Durham, S. R. et al. Long-term clinical efficacy of grass-pollen immunotherapy. N. Engl. J. Med. 341, 468-475 (1999).
4. Bluestone, J. A. & Matthews, J. B. The immune tolerance network \-an NIH/JDF-supported initiative to bring tolerance research into the clinic: a major new resource for clinical immunologists. Clin. Immunol. 96, 171-173 (2000).
5. Herold, K. C. et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N. Engl. J. Med. 346, 1692-1698 (2002).
6. Herold, K. C. et al. Treatment of patients with new onset type 1 diabetes with a single course of anti-CD3 mAb teplizumab preserves insulin production for up to 5 years. Clin. Immunol. 132, 166-173 (2009).
7. Utset, T. O. et al. Modified anti-CD3 therapy in psoriatic arthritis: a phase I/II clinical trial. J. Rheumatol. 29, 1907-1913 (2002).
8. You, S. et al. Adaptive TGF-β-dependent regulatory T cells control autoimmune diabetes and are a privileged target of anti-CD3 antibody treatment. Proc. Natl Acad. Sci. USA 104, 6335-6340 (2007).
9. Morelon, E. et al. Preferential increase in memory and regulatory subsets during T-lymphocyte immune reconstitution after Thymoglobulin induction therapy with maintenance sirolimus vs cyclosporine. Transpl. Immunol. 23, 53-58 (2010).
10. Rothstein, D. M. & Sayegh, M. H. T-cell costimulatory pathways in allograft rejection and tolerance. Immunol. R ev. 196, 85-108 (2003).
11. Sidiropoulos, P. I. & Boumpas, D. T. Lessons learned from anti-CD40L treatment in systemic lupus erythematosus patients. Lupus 13, 391-397 (2004).
12. Viglietta, V. et al. CTLA4Ig treatment in patients with multiple sclerosis: an open-label, phase 1 clinical trial. Neurology 71, 917-924 (2008).
13. Tang, Q. et al. Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity 28, 687-697 (2008).
14. Rabinovitch, A., Suarez-Pinzon, W. L., Shapiro, A. M., Rajotte, R. V. & Power, R. Combination therapy with sirolimus and interleukin-2 prevents spontaneous and recurrent autoimmune diabetes in NOD mice. Diabetes 51, 638-645 (2002).
15. + regulatory T cells of both healthy subjects and type 1 diabetic patients. J. Immunol. 177, 8338-8347 (2006).
16. Weaver, T. A. et al. Alefacept promotes co-stimulation blockade based allograft survival in nonhuman primates. Nature Med. 15, 746-749 (2009).
17. Stone, J. H. et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N. Engl. J. Med. 363, 221-232 (2010).
18. H2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 420, 78-84 (2002).
19. Waubant, E. et al. Atorvastatin therapy in patients with clinically isolated syndrome and high-risk for conversion to multiple sclerosis: the STAyCIS study. Multiple Sclerosis 15, S271-S277 (2009).
20. Louvet, C. et al. Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice. Proc. Natl Acad. Sci. USA 105, 18895-18900 (2008).
21. Koulmanda, M. et al. Curative and beta cell regenerative effects of α1-antitrypsin treatment in autoimmune diabetic NOD mice. Proc. Natl Acad. Sci. USA 105, 16242-16247 (2008).
22. Valentine, M. D. et al. The value of immunotherapy with venom in children with allergy to insect stings. N. Engl. J. Med. 323, 1601-1603 (1990).
23. Casale, T. B. et al. Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J. Allergy Clin. Immunol. 11 7 , 134-140 (2006).
24. Creticos, P. S. et al. Immunotherapy with a ragweed-Toll-like receptor 9 agonist vaccine for allergic rhinitis. N. Engl. J. Med. 355, 1445-1455 (2006).
25. Billingham, R. E., Brent, L. & Medawar, P. B. Actively acquired tolerance of foreign cells. Nature 172, 603-606 (1953).
26. Du Toit, G. et al. Early consumption of peanuts in infancy is associated with a low prevalence of peanut allergy. J. Allergy Clin. Immunol. 122, 984-991 (2008).
27. Kawai, T. et al. HLA-mismatched renal transplantation without maintenance immunosuppression. N. Engl. J. Med. 358, 353-361 (2008).
28. Fudaba, Y. et al. Myeloma responses and tolerance following combined kidney and nonmyeloablative marrow transplantation: in vivo and in vitro analyses. Am. J. Transplant. 6, 2121-2133 (2006).
29. Knechtle, S. J. et al. Early and limited use of tacrolimus to avoid rejection in an alemtuzumab and sirolimus regimen for kidney transplantation: clinical results and immune monitoring. Am. J. Transplant. 9, 1087-1098 (2009).
30. Feng, S. et al. ITN029ST: Immunosuppression withdrawal in pediatric recipients of parental living donor liver transplants: preliminary results of a pilot study. Abstract No. 189 (American Transplant Congress, Boston, Massachusetts, 2009).
31. Newell, K. A. et al. Identification of a B cell signature associated with renal transplant tolerance in humans. J. Clin. Invest. 120, 1836-1847 (2010).
32. Sagoo, P. et al. Development of a cross-platform biomarker signature to detect renal transplant tolerance in humans. J. Clin. Invest. 120, 1848-1861 (2010).
33. Sanchez-Fueyo, A. Identification of tolerant recipients following liver transplantation. Int. Immunopharmacol. 29 Jun 2010 (doi:10.1016/j. intimp.2010.06.011).
34. Gebauer, B. S. et al. Evolution of the enzyme-linked immunosorbent spot assay for post-transplant alloreactivity as a potentially useful immune monitoring tool. Am. J. Transplant. 2, 857-866 (2002).
35. Ding, R. et al. CD103 mRNA levels in urinary cells predict acute rejection of renal allografts. Transplantation 75, 1307-1312 (2003).
36. Mazariegos, G. V. et al. Dendritic cell subset ratio in peripheral blood correlates with successful withdrawal of immunosuppression in liver transplant patients. Am. J. Transplant. 3, 689-696 (2003).
37. Muthukumar, T. et al. Serine proteinase inhibitor-9, an endogenous blocker of granzyme B/perforin lytic pathway, is hyperexpressed during acute rejection of renal allografts. Transplantation 75, 1565-1570 (2003).
38. Reijonen, H. & Kwok, W. W. Use of HLA class II tetramers in tracking antigen-specific T cells and mapping T-cell epitopes. Methods 29, 282-288 (2003).
39. Yang, J., Jaramillo, A., Shi, R., Kwok, W. W. & Mohanakumar, T. In vivo biotinylation of the major histo-compatibility complex (MHC) class II/peptide complex by co-expression of BirA enzyme for the generation of MHC class II/tetramers. Hum. Immunol. 65, 692-699 (2004).
40. Seyfert-Margolis, V. et al. Analysis of T cell assays to measure autoimmune responses in subjects with type 1 diabetes: results of a blinded controlled study. Diabetes 55, 2588-2594 (2006).
41. Shamji, M. H. et al. The IgE-facilitated allergen binding (FAB) assay: validation of a novel flow-cytometric based assay for the detection of inhibitory antibody responses. J. Immunol. Methods 317, 71-79 (2006).
42. Shapiro, A. M. J. et al. International multicenter trial of islet transplantation with the Edmonton protocol in type 1 diabetes. N. Engl. J. Med. 355, 1318-1330 (2006).
43. Klunker, S. et al. Combination treatment with omalizumab and rush immunotherapy for ragweed-induced allergic rhinitis: inhibition of IgE-facilitated allergen binding. J. Allergy Clin. Immunol. 120, 688-695 (2007).
44. Zhang, L. et al. A robust immunoassay for anti-interferon autoantibodies that is highly specific for patients with autoimmune polyglandular syndrome type 1. Clin. Immunol. 125, 131-137 (2007).
45. Porcheray, F. et al. B-cell immunity in the context of T-cell tolerance after combined kidney and bone marrow transplantation in humans. Am. J. Transplant. 9, 2126-2135 (2009).